Literature DB >> 8868212

Neuroleptic malignant syndrome after neuroleptic discontinuation.

M Amore1, N Zazzeri.   

Abstract

1. Neuroleptic withdrawal can cause autonomic and behavioral symptoms (nausea, vomiting, diarrhea, diaphoresis, myalgia, anxiety, restlessness) and movement disorders (withdrawal emergent parkinsonism, withdrawal dyskinesia, covert dyskinesia). 2. Neuroleptic malignant syndrome (NMS) is a rare but extremely severe adverse reaction to neuroleptic drugs characterized by extrapyramidal and autonomic symptoms, altered level of consciousness and abnormal laboratory findings. 3. Withdrawal neuroleptic malignant syndrome, though an even rarer condition (only 7 cases reported to date), should alert to consider the possibility that abrupt neuroleptic discontinuation can be complicated by NMS. 4. The pathophysiology of withdrawal medical symptoms may be related to a cholinergic rebound; withdrawal neuroleptic malignant syndrome may be attributed to an "imbalance" in the dopaminergic system. 5. The authors report two cases of NMS precipitated by the abrupt withdrawal of neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8868212     DOI: 10.1016/0278-5846(95)00269-3

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

Review 1.  Diagnosis and treatment of viral encephalitis.

Authors:  A Chaudhuri; P G E Kennedy
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

2.  State of the Globe: Acute Febrile Encephalopathy.

Authors:  Avinash Agarwal; Manish Gutch; Sukriti Kumar; Shuchi Agrawal
Journal:  J Glob Infect Dis       Date:  2016 Oct-Dec

3.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

Review 4.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

5.  "Brief" Aripiprazole-induced Neuroleptic Malignant Syndrome with Symptoms that Only Lasted a Few Hours.

Authors:  Naoto Mizumura; Masato Uematsu; Aya Ito; Satoshi Okumura; Hiromitsu Maehira; Masao Ogawa; Masayasu Kawasaki
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

6.  Probable case of neuroleptic malignant syndrome following administration of antituberculotic drugs in a chlorpromazine-treated patient.

Authors:  GeumSook Shim; Do-Hyung Kang; Jun Soo Kwon
Journal:  J Korean Med Sci       Date:  2008-08       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.